Skip to main
ATOS
ATOS logo

Atossa Genetics (ATOS) Stock Forecast & Price Target

Atossa Genetics (ATOS) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Atossa Therapeutics Inc. is positioned favorably due to its focus on developing innovative treatments in oncology and COVID-19, specifically its lead drug Endoxifen and two promising COVID-19 therapies, AT-H201 and AT-301. The company's current valuation is deemed attractive, supported by a recent adjustment in the price target reflecting a positive net present value analysis. Anticipated progress in key clinical milestones is expected to drive further investor interest and bolster the stock's potential.

Bears say

Atossa Therapeutics reported a net loss of $8.4 million, which translates to an earnings per share (EPS) of $(0.07), falling short of both internal and consensus estimates of $(0.06). The company's financial outlook is further compounded by a multitude of risks, including significant balance sheet and liquidity concerns, potential failures in clinical trials affecting product safety and efficacy, and challenges in obtaining regulatory approvals. Additionally, the landscape of biotechnology investments remains precarious, influenced by ongoing competition, shifting macroeconomic conditions, and changes in healthcare priorities, all of which could adversely affect the company's ability to commercialize its product candidates.

Atossa Genetics (ATOS) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Atossa Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Atossa Genetics (ATOS) Forecast

Analysts have given Atossa Genetics (ATOS) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Atossa Genetics (ATOS) has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Atossa Genetics (ATOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.